Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WH9U
|
|||
| Former ID |
DIB008486
|
|||
| Drug Name |
FK-070
|
|||
| Synonyms |
KDI-792; Kdi 792; FK 070; FK-070; AC1O5X7F; SCHEMBL8657761; JGCFJVFIRFTRKJ-YOLZMAEBSA-N; 130047-30-2; FR-121070; 167678-84-4; (2S,4R)-2-[(Z)-5-carboxy-1-pentenyl]-4-(4-chlorophenylsulfonylamino)-1-(3-pyridylmethyl)pyrrolidine hydrochloride; 5-Hexenoic acid, 6-((2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1-(3- pyridinylmethyl)-2-pyrrolidinyl)-, monohydrochloride, (5Z)-; 178895-18-6; (Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Angina pectoris [ICD-11: BA40; ICD-9: 413] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H27Cl2N3O4S
|
|||
| Canonical SMILES |
C1C(CN(C1C=CCCCC(=O)O)CC2=CN=CC=C2)NS(=O)(=O)C3=CC=C(C=C3)Cl.Cl
|
|||
| InChI |
1S/C22H26ClN3O4S.ClH/c23-18-8-10-21(11-9-18)31(29,30)25-19-13-20(6-2-1-3-7-22(27)28)26(16-19)15-17-5-4-12-24-14-17;/h2,4-6,8-12,14,19-20,25H,1,3,7,13,15-16H2,(H,27,28);1H/b6-2-;/t19-,20-;/m1./s1
|
|||
| InChIKey |
JGCFJVFIRFTRKJ-YOLZMAEBSA-N
|
|||
| CAS Number |
CAS 130047-30-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thromboxane A2 receptor (TBXA2R) | Target Info | Modulator | [1] |
| Thromboxane-A synthase (TBXAS1) | Target Info | Modulator | [1] | |
| BioCyc | C20 prostanoid biosynthesis | |||
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Platelet activation | ||||
| Arachidonic acid metabolism | ||||
| Metabolic pathways | ||||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| Thromboxane signalling through TP receptor | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| Signal amplification | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Prostaglandin Synthesis and Regulation | ||||
| Arachidonic acid metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| Eicosanoid Synthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.